Ronald Vagnozzi
Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Cardiac | 22 | 2026 | 556 | 3.460 |
Why?
| | Myocardium | 12 | 2024 | 939 | 1.690 |
Why?
| | Fibrosis | 12 | 2024 | 548 | 1.530 |
Why?
| | Macrophages | 10 | 2024 | 1511 | 1.420 |
Why?
| | Myocardial Infarction | 11 | 2026 | 1209 | 1.330 |
Why?
| | Ventricular Remodeling | 11 | 2024 | 276 | 1.290 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2021 | 80 | 1.260 |
Why?
| | Stem Cell Transplantation | 2 | 2021 | 191 | 1.190 |
Why?
| | Adult Stem Cells | 2 | 2018 | 39 | 1.110 |
Why?
| | Immunity, Innate | 3 | 2021 | 846 | 0.950 |
Why?
| | Biomedical Research | 2 | 2024 | 710 | 0.900 |
Why?
| | Cell Differentiation | 8 | 2024 | 2050 | 0.800 |
Why?
| | Cardiomyopathies | 3 | 2023 | 338 | 0.770 |
Why?
| | Myofibroblasts | 6 | 2024 | 143 | 0.760 |
Why?
| | Sirtuin 3 | 1 | 2023 | 60 | 0.760 |
Why?
| | Homeostasis | 3 | 2021 | 640 | 0.760 |
Why?
| | Heart | 5 | 2020 | 636 | 0.740 |
Why?
| | T-Lymphocytes | 2 | 2022 | 1982 | 0.730 |
Why?
| | American Heart Association | 1 | 2024 | 350 | 0.730 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2021 | 11 | 0.690 |
Why?
| | Monocytes | 2 | 2020 | 538 | 0.660 |
Why?
| | Immunity, Humoral | 1 | 2021 | 120 | 0.630 |
Why?
| | Myocarditis | 1 | 2021 | 102 | 0.630 |
Why?
| | Myeloid Cells | 1 | 2020 | 148 | 0.610 |
Why?
| | Immunity, Cellular | 1 | 2021 | 272 | 0.600 |
Why?
| | Antigens, Ly | 1 | 2018 | 40 | 0.580 |
Why?
| | Animals | 44 | 2026 | 38058 | 0.570 |
Why?
| | Mice | 34 | 2026 | 18339 | 0.560 |
Why?
| | Running | 1 | 2020 | 228 | 0.550 |
Why?
| | Congresses as Topic | 1 | 2019 | 221 | 0.540 |
Why?
| | Myocardial Ischemia | 3 | 2015 | 285 | 0.540 |
Why?
| | Immunotherapy | 1 | 2022 | 653 | 0.510 |
Why?
| | Fibroblasts | 5 | 2024 | 1034 | 0.480 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 337 | 0.470 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 668 | 0.460 |
Why?
| | Glycogen Synthase Kinase 3 | 5 | 2014 | 81 | 0.460 |
Why?
| | Stem Cells | 1 | 2019 | 626 | 0.440 |
Why?
| | Membrane Proteins | 2 | 2018 | 1166 | 0.440 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4557 | 0.410 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 70 | 0.390 |
Why?
| | Extracellular Matrix | 6 | 2021 | 553 | 0.390 |
Why?
| | Cardiovascular Diseases | 3 | 2023 | 2168 | 0.380 |
Why?
| | Endothelium, Vascular | 2 | 2018 | 965 | 0.370 |
Why?
| | Mice, Inbred C57BL | 17 | 2026 | 5992 | 0.370 |
Why?
| | Protein Kinases | 1 | 2013 | 315 | 0.350 |
Why?
| | Gene Deletion | 5 | 2017 | 389 | 0.330 |
Why?
| | Cell Communication | 2 | 2024 | 324 | 0.330 |
Why?
| | Rodentia | 2 | 2021 | 61 | 0.320 |
Why?
| | Mice, Transgenic | 10 | 2023 | 2182 | 0.320 |
Why?
| | Aging | 5 | 2020 | 1966 | 0.320 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2024 | 137 | 0.300 |
Why?
| | Cell Lineage | 4 | 2020 | 376 | 0.280 |
Why?
| | Regeneration | 4 | 2020 | 197 | 0.280 |
Why?
| | Coronary Vessels | 2 | 2021 | 251 | 0.270 |
Why?
| | Heart Failure | 5 | 2024 | 2323 | 0.270 |
Why?
| | Mitochondria | 5 | 2020 | 984 | 0.260 |
Why?
| | Oxidative Stress | 1 | 2013 | 1339 | 0.250 |
Why?
| | Myocardial Contraction | 4 | 2015 | 298 | 0.250 |
Why?
| | Cells, Cultured | 9 | 2024 | 4154 | 0.240 |
Why?
| | Iodide Peroxidase | 1 | 2026 | 34 | 0.230 |
Why?
| | Signal Transduction | 7 | 2024 | 5226 | 0.230 |
Why?
| | Nanotubes, Carbon | 1 | 2025 | 48 | 0.220 |
Why?
| | Mice, Knockout | 10 | 2026 | 3121 | 0.210 |
Why?
| | Azepines | 1 | 2024 | 107 | 0.210 |
Why?
| | Heart Diseases | 2 | 2017 | 349 | 0.210 |
Why?
| | Chordata | 1 | 2023 | 5 | 0.200 |
Why?
| | Cell Cycle Proteins | 2 | 2024 | 628 | 0.200 |
Why?
| | Injections | 2 | 2025 | 196 | 0.200 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2024 | 109 | 0.200 |
Why?
| | Calcium Channels | 2 | 2015 | 154 | 0.200 |
Why?
| | Iron-Binding Proteins | 1 | 2023 | 43 | 0.200 |
Why?
| | Triazoles | 1 | 2024 | 184 | 0.200 |
Why?
| | Bone Marrow Transplantation | 2 | 2021 | 294 | 0.190 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2024 | 364 | 0.190 |
Why?
| | Calcium | 3 | 2015 | 1183 | 0.190 |
Why?
| | Nuclear Proteins | 2 | 2024 | 748 | 0.190 |
Why?
| | Collagen Type I | 1 | 2023 | 147 | 0.190 |
Why?
| | Arteries | 2 | 2023 | 259 | 0.190 |
Why?
| | Ventricular Function, Right | 1 | 2025 | 297 | 0.180 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2014 | 392 | 0.180 |
Why?
| | Mitochondrial Membrane Transport Proteins | 2 | 2013 | 46 | 0.180 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2025 | 248 | 0.180 |
Why?
| | Career Choice | 1 | 2024 | 237 | 0.170 |
Why?
| | Hypertension, Pulmonary | 2 | 2025 | 1980 | 0.170 |
Why?
| | Biocompatible Materials | 1 | 2025 | 435 | 0.170 |
Why?
| | Tissue Engineering | 1 | 2025 | 442 | 0.160 |
Why?
| | Phagocytes | 1 | 2021 | 81 | 0.160 |
Why?
| | Transcription Factors | 3 | 2024 | 1741 | 0.160 |
Why?
| | Arteritis | 1 | 2020 | 25 | 0.160 |
Why?
| | Chromatin | 1 | 2024 | 561 | 0.160 |
Why?
| | Smad3 Protein | 2 | 2017 | 43 | 0.160 |
Why?
| | Treatment Failure | 1 | 2021 | 365 | 0.160 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 320 | 0.160 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2021 | 138 | 0.160 |
Why?
| | Gene Transfer Techniques | 1 | 2021 | 185 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 357 | 0.150 |
Why?
| | Rejuvenation | 1 | 2019 | 18 | 0.150 |
Why?
| | Marfan Syndrome | 1 | 2020 | 46 | 0.150 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2019 | 6 | 0.150 |
Why?
| | HSP47 Heat-Shock Proteins | 1 | 2019 | 6 | 0.150 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 194 | 0.150 |
Why?
| | Boston | 1 | 2019 | 92 | 0.150 |
Why?
| | Humans | 21 | 2026 | 144759 | 0.150 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 207 | 0.150 |
Why?
| | Collagen | 2 | 2019 | 456 | 0.150 |
Why?
| | Genetic Engineering | 1 | 2019 | 93 | 0.150 |
Why?
| | Cell Adhesion Molecules | 2 | 2020 | 178 | 0.140 |
Why?
| | Myoblasts, Cardiac | 2 | 2018 | 3 | 0.140 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 383 | 0.140 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 573 | 0.140 |
Why?
| | Heart Valve Diseases | 1 | 2020 | 151 | 0.140 |
Why?
| | Male | 18 | 2026 | 72315 | 0.140 |
Why?
| | Yolk Sac | 1 | 2018 | 5 | 0.140 |
Why?
| | Cell Self Renewal | 1 | 2018 | 53 | 0.140 |
Why?
| | Vascular Remodeling | 2 | 2021 | 205 | 0.140 |
Why?
| | Regenerative Medicine | 1 | 2018 | 50 | 0.140 |
Why?
| | Muscle Development | 1 | 2018 | 116 | 0.140 |
Why?
| | Cell Movement | 3 | 2018 | 965 | 0.140 |
Why?
| | Ischemia | 1 | 2021 | 421 | 0.140 |
Why?
| | Hydrogels | 1 | 2025 | 700 | 0.130 |
Why?
| | Cell Transdifferentiation | 1 | 2017 | 31 | 0.130 |
Why?
| | Smad2 Protein | 1 | 2017 | 37 | 0.130 |
Why?
| | Cicatrix | 1 | 2018 | 69 | 0.130 |
Why?
| | Cardiomegaly | 4 | 2023 | 174 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 2 | 2014 | 72 | 0.130 |
Why?
| | Models, Animal | 1 | 2018 | 392 | 0.130 |
Why?
| | Embryonic Stem Cells | 1 | 2018 | 130 | 0.130 |
Why?
| | Actin Cytoskeleton | 2 | 2015 | 103 | 0.120 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2016 | 10 | 0.120 |
Why?
| | Isoproterenol | 1 | 2016 | 97 | 0.120 |
Why?
| | RNA, Messenger | 2 | 2022 | 2832 | 0.120 |
Why?
| | Cellular Reprogramming | 1 | 2016 | 103 | 0.120 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 65 | 0.110 |
Why?
| | Enzyme Activation | 2 | 2014 | 766 | 0.110 |
Why?
| | Aorta, Thoracic | 2 | 2015 | 286 | 0.110 |
Why?
| | Chronic Disease | 1 | 2021 | 1813 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 2 | 2013 | 969 | 0.110 |
Why?
| | Nanoparticles | 1 | 2021 | 519 | 0.110 |
Why?
| | Muscle Proteins | 1 | 2016 | 244 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 479 | 0.110 |
Why?
| | Heart Ventricles | 1 | 2019 | 760 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2015 | 124 | 0.100 |
Why?
| | Melanosomes | 1 | 2014 | 2 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 310 | 0.100 |
Why?
| | Concanavalin A | 1 | 2014 | 71 | 0.100 |
Why?
| | Pigment Epithelium of Eye | 1 | 2014 | 36 | 0.100 |
Why?
| | Protein Isoforms | 1 | 2015 | 402 | 0.100 |
Why?
| | Heart Injuries | 1 | 2014 | 42 | 0.100 |
Why?
| | Niacinamide | 1 | 2014 | 86 | 0.100 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 112 | 0.100 |
Why?
| | Cell Nucleus | 1 | 2016 | 618 | 0.100 |
Why?
| | Superoxides | 1 | 2013 | 204 | 0.100 |
Why?
| | Cation Transport Proteins | 1 | 2013 | 118 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 266 | 0.090 |
Why?
| | Small Molecule Libraries | 1 | 2013 | 111 | 0.090 |
Why?
| | Calcium-Binding Proteins | 1 | 2013 | 219 | 0.090 |
Why?
| | Cell Proliferation | 5 | 2020 | 2496 | 0.090 |
Why?
| | Heart Rupture | 1 | 2011 | 4 | 0.090 |
Why?
| | Cell Death | 1 | 2013 | 383 | 0.090 |
Why?
| | Female | 9 | 2026 | 78271 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2015 | 409 | 0.090 |
Why?
| | Sarcopenia | 1 | 2013 | 91 | 0.090 |
Why?
| | Up-Regulation | 1 | 2013 | 851 | 0.080 |
Why?
| | Cyclophilins | 1 | 2010 | 40 | 0.080 |
Why?
| | Acute Coronary Syndrome | 1 | 2013 | 293 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2021 | 11679 | 0.070 |
Why?
| | Single-Cell Analysis | 2 | 2024 | 358 | 0.070 |
Why?
| | Indoles | 2 | 2013 | 501 | 0.070 |
Why?
| | Pyrroles | 1 | 2009 | 217 | 0.070 |
Why?
| | Energy Metabolism | 1 | 2013 | 935 | 0.070 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 190 | 0.070 |
Why?
| | Primary Cell Culture | 2 | 2019 | 173 | 0.060 |
Why?
| | Phenotype | 3 | 2024 | 3162 | 0.060 |
Why?
| | Triiodothyronine | 1 | 2026 | 54 | 0.060 |
Why?
| | Animals, Newborn | 2 | 2020 | 902 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 2 | 2020 | 420 | 0.060 |
Why?
| | Cell Fusion | 2 | 2016 | 49 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2026 | 67 | 0.060 |
Why?
| | Endothelial Cells | 3 | 2019 | 869 | 0.060 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2024 | 19 | 0.050 |
Why?
| | Transcription Factor RelA | 1 | 2024 | 85 | 0.050 |
Why?
| | Inflammation | 1 | 2015 | 2878 | 0.050 |
Why?
| | Lipoylation | 1 | 2023 | 17 | 0.050 |
Why?
| | Histidine | 1 | 2023 | 66 | 0.050 |
Why?
| | Particle Size | 1 | 2025 | 411 | 0.050 |
Why?
| | Materials Testing | 1 | 2025 | 354 | 0.050 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2023 | 56 | 0.050 |
Why?
| | Acyltransferases | 1 | 2023 | 78 | 0.050 |
Why?
| | Neuropeptides | 1 | 2023 | 77 | 0.050 |
Why?
| | Enhancer Elements, Genetic | 1 | 2024 | 192 | 0.050 |
Why?
| | Echocardiography | 2 | 2021 | 652 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1782 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2194 | 0.050 |
Why?
| | Heart Atria | 1 | 2023 | 144 | 0.050 |
Why?
| | Rats | 3 | 2019 | 5597 | 0.050 |
Why?
| | Interleukin-1beta | 1 | 2024 | 395 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 276 | 0.040 |
Why?
| | Temperature | 1 | 2025 | 679 | 0.040 |
Why?
| | Acclimatization | 1 | 2023 | 172 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2013 | 75 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2021 | 15 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 661 | 0.040 |
Why?
| | Airway Remodeling | 1 | 2021 | 64 | 0.040 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2021 | 150 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2024 | 523 | 0.040 |
Why?
| | Transplantation Chimera | 1 | 2020 | 56 | 0.040 |
Why?
| | Drug Carriers | 1 | 2021 | 130 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2013 | 139 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 202 | 0.040 |
Why?
| | Fibrillin-1 | 1 | 2020 | 6 | 0.040 |
Why?
| | Hypertrophy | 1 | 2020 | 127 | 0.040 |
Why?
| | Angiotensin II | 1 | 2020 | 97 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2847 | 0.040 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 88 | 0.040 |
Why?
| | Multiprotein Complexes | 2 | 2013 | 172 | 0.040 |
Why?
| | Sarcoglycans | 1 | 2019 | 5 | 0.040 |
Why?
| | Adipokines | 1 | 2020 | 57 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2020 | 115 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.040 |
Why?
| | Mitral Valve | 1 | 2020 | 96 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2021 | 313 | 0.040 |
Why?
| | Bone Marrow | 1 | 2020 | 304 | 0.040 |
Why?
| | Zebrafish | 1 | 2023 | 528 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2112 | 0.040 |
Why?
| | Dogs | 1 | 2020 | 437 | 0.040 |
Why?
| | Blood Circulation | 1 | 2018 | 44 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 442 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 684 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2013 | 449 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 380 | 0.030 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 57 | 0.030 |
Why?
| | Swine | 1 | 2020 | 833 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 232 | 0.030 |
Why?
| | Mice, Inbred mdx | 1 | 2016 | 12 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 158 | 0.030 |
Why?
| | Organ Specificity | 1 | 2017 | 312 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2608 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2018 | 321 | 0.030 |
Why?
| | Catecholamines | 1 | 2016 | 87 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2016 | 86 | 0.030 |
Why?
| | Muscle, Skeletal | 2 | 2019 | 1795 | 0.030 |
Why?
| | Protein Phosphatase 2C | 1 | 2015 | 15 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 7173 | 0.030 |
Why?
| | Apoptosis | 2 | 2014 | 2430 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2015 | 61 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 94 | 0.030 |
Why?
| | Ventricular Myosins | 1 | 2015 | 39 | 0.030 |
Why?
| | Myofibrils | 1 | 2015 | 49 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 905 | 0.030 |
Why?
| | Sarcomeres | 1 | 2015 | 98 | 0.030 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2016 | 214 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2015 | 60 | 0.030 |
Why?
| | Proteins | 2 | 2013 | 1021 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2015 | 135 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2014 | 121 | 0.030 |
Why?
| | Metoprolol | 1 | 2014 | 26 | 0.030 |
Why?
| | Cytoplasmic Streaming | 1 | 2014 | 2 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2014 | 72 | 0.030 |
Why?
| | Cell Aggregation | 1 | 2014 | 19 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2015 | 261 | 0.030 |
Why?
| | Perciformes | 1 | 2014 | 19 | 0.030 |
Why?
| | Cats | 1 | 2014 | 228 | 0.030 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 266 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2882 | 0.030 |
Why?
| | Integrases | 1 | 2014 | 122 | 0.020 |
Why?
| | Maleimides | 1 | 2013 | 21 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 224 | 0.020 |
Why?
| | Tamoxifen | 1 | 2014 | 217 | 0.020 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2015 | 452 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 498 | 0.020 |
Why?
| | Everolimus | 1 | 2013 | 111 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 213 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1047 | 0.020 |
Why?
| | HeLa Cells | 1 | 2013 | 650 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2015 | 453 | 0.020 |
Why?
| | Hepatocytes | 1 | 2013 | 223 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 635 | 0.020 |
Why?
| | Cardiotonic Agents | 1 | 2011 | 95 | 0.020 |
Why?
| | Sirolimus | 1 | 2013 | 281 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1732 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 186 | 0.020 |
Why?
| | Death | 1 | 2011 | 130 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2013 | 226 | 0.020 |
Why?
| | Autophagy | 1 | 2013 | 286 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 965 | 0.020 |
Why?
| | Binding Sites | 1 | 2013 | 1329 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1716 | 0.020 |
Why?
| | Bone and Bones | 1 | 2013 | 314 | 0.020 |
Why?
| | Mitochondria, Heart | 1 | 2010 | 102 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4271 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2027 | 0.020 |
Why?
| | Knee Joint | 1 | 2013 | 426 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2009 | 91 | 0.020 |
Why?
| | Myosin Heavy Chains | 1 | 2010 | 185 | 0.020 |
Why?
| | Exons | 1 | 2010 | 358 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2010 | 217 | 0.020 |
Why?
| | Cell Division | 1 | 2010 | 766 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 124 | 0.020 |
Why?
| | DNA | 1 | 2014 | 1463 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 2273 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1821 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1098 | 0.010 |
Why?
| | Biopsy | 1 | 2009 | 1075 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1257 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1887 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 2527 | 0.010 |
Why?
| | Adult | 1 | 2023 | 40449 | 0.010 |
Why?
| | Aged | 1 | 2014 | 25913 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 35875 | 0.010 |
Why?
|
|
Vagnozzi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|